AU2022222679A1 - Methods and materials for treating clonal t cell expansions - Google Patents

Methods and materials for treating clonal t cell expansions Download PDF

Info

Publication number
AU2022222679A1
AU2022222679A1 AU2022222679A AU2022222679A AU2022222679A1 AU 2022222679 A1 AU2022222679 A1 AU 2022222679A1 AU 2022222679 A AU2022222679 A AU 2022222679A AU 2022222679 A AU2022222679 A AU 2022222679A AU 2022222679 A1 AU2022222679 A1 AU 2022222679A1
Authority
AU
Australia
Prior art keywords
polypeptide
antigen binding
binding domain
bind
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022222679A
Other languages
English (en)
Inventor
Michael S. HWANG
Kenneth W. Kinzler
Brian J. MOG
Nickolas Papadopoulos
Andrew PARDOLL
Suman PAUL
Bert Vogelstein
Shibin Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2022222679A1 publication Critical patent/AU2022222679A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022222679A 2021-02-17 2022-02-15 Methods and materials for treating clonal t cell expansions Pending AU2022222679A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150232P 2021-02-17 2021-02-17
US63/150,232 2021-02-17
PCT/US2022/016423 WO2022177889A1 (en) 2021-02-17 2022-02-15 Methods and materials for treating clonal t cell expansions

Publications (1)

Publication Number Publication Date
AU2022222679A1 true AU2022222679A1 (en) 2023-09-07

Family

ID=80595091

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022222679A Pending AU2022222679A1 (en) 2021-02-17 2022-02-15 Methods and materials for treating clonal t cell expansions

Country Status (7)

Country Link
US (1) US20240124608A1 (enExample)
EP (1) EP4294841A1 (enExample)
JP (1) JP2024508749A (enExample)
CN (1) CN117561277A (enExample)
AU (1) AU2022222679A1 (enExample)
CA (1) CA3211203A1 (enExample)
WO (1) WO2022177889A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
JP2026524330A (ja) * 2023-06-28 2026-07-22 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｔｒｂｃ標的化抗体薬物複合体
WO2025220689A1 (ja) * 2024-04-17 2025-10-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞機能不全のｔ細胞性腫瘍患者に有効な二重特異性抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2744046C2 (ru) * 2014-03-05 2021-03-02 Отолус Лимитед ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА
GB201709203D0 (en) * 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
GB201817172D0 (en) * 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) * 2018-10-31 2018-12-19 Autolus Ltd Binding domain

Also Published As

Publication number Publication date
JP2024508749A (ja) 2024-02-28
WO2022177889A1 (en) 2022-08-25
CN117561277A (zh) 2024-02-13
US20240124608A1 (en) 2024-04-18
EP4294841A1 (en) 2023-12-27
CA3211203A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
AU2018250336B2 (en) Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
US20240124608A1 (en) Methods and materials for treating clonal t cell expansions
KR20200026810A (ko) Msln 표적화 삼중 특이적 단백질 및 사용 방법
JP2017081926A (ja) Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用
CN116672445A (zh) 连接蛋白(Cx)43半通道结合抗体及其用途
EP3691661A1 (en) Combination for t-cell immunotherapy and use thereof
JP2018512397A (ja) 癌治療の有効性を高めるための組成物及び方法
US20120052515A1 (en) Therapeutic applications of noncovalent dimerizing antibodies
US20240156863A1 (en) Sequential anti-cd19 therapy
CN111683677A (zh) 使用抗体-药物缀合物调节免疫应答
CN112351795A (zh) 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
US20250034252A1 (en) Manabodies targeting p53 tumor antigens and methods of using
WO2022119955A1 (en) Methods and materials for treating t cell cancers
JP2025072466A (ja) 抗ｃｄ１２３免疫複合体を用いた治療法
JP2025128349A (ja) 二重特異性タンパク質
EP3740501A1 (en) Fusion protein extensions
JP7533330B2 (ja) Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
EP4135769A1 (en) Immune cell redirecting compositions and therapeutic uses thereof
CA3127142A1 (en) Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies
AU2007209787B2 (en) Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
WO2025217204A1 (en) Methods and materials for treating p53+ cancers
EA042472B1 (ru) Триспецифические связанные белки и способы их применения